Krystal Biotech, Inc. Total Liabilities and Equity
Krystal Biotech, Inc. (KRYS) had Total Liabilities and Equity of $1.50 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-03
- 2026-06-30: Liabilities and Equity $1.50B.
- 2026-03-31: Liabilities and Equity $1.40B.
- 2025-12-31: Liabilities and Equity $1.33B.
- 2025-09-30: Liabilities and Equity $1.24B.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $1.50B 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.40B 10-Q · filed 2026-05-04 |
| 2025-12-31 | $1.33B 10-Q · filed 2026-08-03 |
| 2025-09-30 | $1.24B 10-Q · filed 2025-11-03 |
| 2025-06-30 | $1.14B 10-Q · filed 2025-08-04 |
| 2025-03-31 | $1.07B 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.06B 10-K · filed 2026-02-17 |
| 2024-09-30 | $982.32M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $917.66M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $853.30M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $818.36M 10-K · filed 2025-02-19 |
| 2023-09-30 | $790.35M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $684.03M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $531.85M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $558.45M 10-K · filed 2024-02-26 |
| 2022-09-30 | $576.38M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $601.32M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $616.87M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $626.29M 10-K · filed 2023-02-27 |
| 2021-09-30 | $451.10M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $443.56M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $443.02M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $310.84M 10-K · filed 2022-02-28 |
| 2020-09-30 | $311.45M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $318.14M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $205.13M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $209.02M 10-K · filed 2021-03-01 |
| 2019-09-30 | $214.23M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $205.16M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $115.70M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $116.12M 10-K · filed 2020-03-10 |
| 2018-09-30 | $54.45M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $46.03M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $47.85M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $50.11M 10-Q · filed 2018-11-05 |
| 2017-09-30 | $52.67M 10-Q · filed 2017-11-13 |
| 2016-12-31 | $2.18M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |